A novel role for an old target: CD45 for breast cancer immunotherapy

Breast cancer subtypes have not shown significant response to current immunomodulatory therapies. Although most subtypes are treatable, triple negative breast cancer (TNBC), an aggressive highly metastatic cancer, comprising 10–20% of breast cancers, remains an unmet medical need. New strategies are...

Descripción completa

Detalles Bibliográficos
Autores principales: Raiter, Annat, Zlotnik, Oran, Lipovetsky, Julia, Mugami, Shany, Dar, Shira, Lubin, Ido, Sharon, Eran, Cohen, Cyrille J., Yerushalmi, Rinat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158046/
https://www.ncbi.nlm.nih.gov/pubmed/34104545
http://dx.doi.org/10.1080/2162402X.2021.1929725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158046/
https://www.ncbi.nlm.nih.gov/pubmed/34104545
http://dx.doi.org/10.1080/2162402X.2021.1929725

Ejemplares similares